Patents Assigned to GLIKNIK INC.
-
Patent number: 11795193Abstract: The present disclosure involves optimized methods for production of biologically active proteins termed optimally manufactured stradomers. The present disclosure further provides compositions and methods useful in the treatment of diseases and conditions including autoimmune diseases, inflammatory diseases, or infectious diseases.Type: GrantFiled: September 14, 2021Date of Patent: October 24, 2023Assignee: Gliknik Inc.Inventors: David S. Block, Emmanuel Y. Mérigeon, Henrik Olsen
-
Patent number: 11331372Abstract: The present invention provides methods for the identification of patients with an inflammatory or autoimmune disease that demonstrate an inadequate response to treatment with a multi-Fc therapeutic, and the determination of an optimal dose of a multi-Fc therapeutic for said patient based on the patient's circulating levels of inactivated C3b (iC3b) and/or additional complement components that may be employed as a surrogate for iC3b based on an analogous response to multi-Fc therapeutics. The present invention further provides for improvements in the use of such multi-Fc therapeutics in the treatment of autoimmune and inflammatory diseases.Type: GrantFiled: December 8, 2017Date of Patent: May 17, 2022Assignee: GLIKNIK INC.Inventors: David S. Block, Henrik Olsen
-
Patent number: 11155574Abstract: The present disclosure involves optimized methods for production of hiologically active proteins termed optimally manufactured stradomers. The present disclosure further provides compositions and methods useful in the treatment of diseases and conditions including autoimmune diseases, inflammatory diseases, or infectious diseases.Type: GrantFiled: December 8, 2017Date of Patent: October 26, 2021Assignee: GLIKNIK INC.Inventors: David S. Block, Emmanuel Y. Mérigeon, Henrik Olsen
-
Patent number: 11117940Abstract: The current invention involves a series of fully recombinant multimerized forms of immunoglobulin Fc which thereby present polyvalent immunoglobulin Fc to immune cell receptors. The fusion proteins exist as both homodimeric and highly ordered multimeric fractions, termed stradomers. In comparison to the homodimeric fraction, purified multimeric stradomers have higher affinity and avidity for Fc?Rs with slower dissociation and are useful in the treatment and prevention of disease. The current invention demonstrates that directly linking IgG1 Fc regions to multimerization domains leads to enhanced multimerization and biological activity.Type: GrantFiled: July 5, 2017Date of Patent: September 14, 2021Assignee: GLIKNIK INC.Inventors: David S. Block, Henrik Olsen
-
Patent number: 11034775Abstract: The present disclosure involves biologically active proteins termed cysteine-optimized multimerizing stradomers. Thus, the present disclosure provides compositions and methods providing anti-autoimmune and anti-inflammatory activities, useful in the treatment of diseases and conditions including autoimmune diseases, inflammatory diseases, or infectious diseases.Type: GrantFiled: June 7, 2017Date of Patent: June 15, 2021Assignee: GLIKNIK INC.Inventors: Henrik Olsen, David S. Block
-
Patent number: 10941191Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.Type: GrantFiled: December 20, 2018Date of Patent: March 9, 2021Assignees: UNIVERSITY OF MARYLAND, BALTIMORE, GLIKNIK INC.Inventors: Scott E. Strome, Dan H. Schulze, David S. Block, Henrik Olsen
-
Patent number: 10851154Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.Type: GrantFiled: June 30, 2016Date of Patent: December 1, 2020Assignees: GLIKNIK INC., UNIVERSITY OF MARYLAND, BALTIMOREInventors: Scott E. Strome, Dan H. Schulze, David S. Block, Henrik Olsen
-
Patent number: 10208105Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.Type: GrantFiled: February 20, 2018Date of Patent: February 19, 2019Assignees: GLIKNIK INC., UNIVERSITY OF MARYLAND, BALTIMOREInventors: Scott E. Strome, Dan H. Schulze, David S. Block, Henrik Olsen
-
Patent number: 9926362Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.Type: GrantFiled: April 10, 2017Date of Patent: March 27, 2018Assignees: Gliknik Inc., University of Maryland, BaltimoreInventors: Scott E. Strome, Dan H. Schulze, David S. Block, Henrik Olsen
-
Patent number: 9683044Abstract: The current invention involves biologically active proteins termed stradobodies. The stradobodies have two or more domains that create stradobody multimers. The stradobodies have both antigen-binding capacity and the ability to bind Fc receptors (FcR), and are useful in the treatment and prevention of disease.Type: GrantFiled: August 20, 2013Date of Patent: June 20, 2017Assignee: GLIKNIK INC.Inventors: David Block, Henrik Olsen
-
Patent number: 9512210Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.Type: GrantFiled: March 20, 2014Date of Patent: December 6, 2016Assignees: GLIKNIK INC., UNIVERSITY OF MARYLAND, BALTIMOREInventors: Scott E. Strome, Dan H. Schulze, David S. Block, Henrik Olsen
-
Patent number: 9512208Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.Type: GrantFiled: September 20, 2013Date of Patent: December 6, 2016Assignees: GLIKNIK INC., University of Maryland, BaltimoreInventors: Scott E. Strome, Dan H. Schulze, David S. Block, Henrik Olsen
-
Publication number: 20150056185Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.Type: ApplicationFiled: March 20, 2014Publication date: February 26, 2015Applicants: GLIKNIK INC., UNIVERSITY OF MARYLAND, BALTIMOREInventors: SCOTT E. STROME, DAN H. SCHULZE, DAVID S. BLOCK
-
Publication number: 20140370012Abstract: The present invention relates to biologically active fusion proteins containing the IgG2 hinge as a multimerization domain capable of multimerizing proteins, peptides and small molecules which are active or more active in multimeric form; compositions comprising such fusion proteins; and methods of making and using such fusion proteins.Type: ApplicationFiled: January 28, 2013Publication date: December 18, 2014Applicant: Gliknik Inc.Inventors: David Block, Henrik Olsen, Scott Strome
-
Publication number: 20140105913Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.Type: ApplicationFiled: September 20, 2013Publication date: April 17, 2014Applicants: GLIKNIK, INC., University of Maryland, BaltimoreInventors: Scott E. STROME, Dan H. Schulze, David S. Block
-
Patent number: 8680237Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.Type: GrantFiled: May 30, 2008Date of Patent: March 25, 2014Assignees: Gliknik Inc., University of Maryland, BaltimoreInventors: Scott E. Strome, Dan H. Schulze, David S. Block, Henrik Olsen
-
Publication number: 20140072582Abstract: The current invention involves biologically active proteins termed stradobodies. The stradobodies have two or more domains that create stradobody multimers. The stradobodies have both antigen-binding capacity and the ability to bind Fc receptors (FcR), and are useful in the treatment and prevention of disease.Type: ApplicationFiled: August 20, 2013Publication date: March 13, 2014Applicant: Gliknik Inc.Inventors: David BLOCK, Henrik OLSEN
-
Publication number: 20120309941Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.Type: ApplicationFiled: May 11, 2012Publication date: December 6, 2012Applicants: GLIKNIK, INC., UNIVERSITY OF MARYLAND, BALTIMOREInventors: SCOTT E. STROME, DAN H. SCHULZE, DAVID S. BLOCK
-
Publication number: 20120121578Abstract: The current invention provides a method of treating a mammal in need of such treatment with aggregated IgG derived from pooled human plasma. The invention further provides using the discarded fraction obtained during the course of standard IgG fractionation as the source of the aggregated IgG. The methods of the invention further provide for enhancing the aggregation of the aggregate fraction as well as enriching and modifying glycoforms.Type: ApplicationFiled: May 13, 2010Publication date: May 17, 2012Applicant: GLIKNIK INC.Inventor: David Block